232 related articles for article (PubMed ID: 23945065)
1. Long-acting injectable antipsychotics: recommendations for clinicians.
Malla A; Tibbo P; Chue P; Levy E; Manchanda R; Teehan M; Williams R; Iyer S; Roy MA
Can J Psychiatry; 2013 May; 58(5 Suppl 1):30S-5S. PubMed ID: 23945065
[TBL] [Abstract][Full Text] [Related]
2. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.
Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
Can J Psychiatry; 2013 May; 58(5 Suppl 1):23S-9S. PubMed ID: 23945064
[TBL] [Abstract][Full Text] [Related]
3. Long-acting injectable antipsychotics: evidence of effectiveness and use.
Manchanda R; Chue P; Malla A; Tibbo P; Roy MA; Williams R; Iyer S; Lutgens D; Banks N
Can J Psychiatry; 2013 May; 58(5 Suppl 1):5S-13S. PubMed ID: 23945067
[TBL] [Abstract][Full Text] [Related]
4. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
[TBL] [Abstract][Full Text] [Related]
5. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
[TBL] [Abstract][Full Text] [Related]
6. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
Kane JM; McEvoy JP; Correll CU; Llorca PM
CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
[TBL] [Abstract][Full Text] [Related]
7. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.
Kane JM; Kishimoto T; Correll CU
J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S37-41. PubMed ID: 23849151
[TBL] [Abstract][Full Text] [Related]
8. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.
Correll CU
J Clin Psychiatry; 2014 Nov; 75(11):e29. PubMed ID: 25470105
[TBL] [Abstract][Full Text] [Related]
9. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.
Suzuki T
Expert Opin Drug Deliv; 2016; 13(2):253-64. PubMed ID: 26636244
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
11. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
[TBL] [Abstract][Full Text] [Related]
12. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
13. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
14. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
Haddad PM; Taylor M; Niaz OS
Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
[TBL] [Abstract][Full Text] [Related]
15. Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
Correll CU; Lauriello J
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505193
[TBL] [Abstract][Full Text] [Related]
16. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
17. Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia.
Kane JM; Correll CU
J Clin Psychiatry; 2019 Sep; 80(5):. PubMed ID: 31536686
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
Stevens GL; Dawson G; Zummo J
Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
[TBL] [Abstract][Full Text] [Related]
19. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
20. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges.
Haddad PM; Correll CU
Expert Opin Pharmacother; 2023 Mar; 24(4):473-493. PubMed ID: 36919576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
